Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

Silo Pharma, Inc. SARASOTA, FLA., July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices’ AMD AI Developer Program. Participation in the program provides access to AMD Developer Cloud credits, advanced AI development tools, training resources, and a global developer community designed to support and accelerate artificial intelligence innovation. “Joining the AMD AI Developer Program represents what we believe is an important step in advancing our QwikAgents platform,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “Access to AMD's AI development resources and cloud infrastructure can help accelerate our ability to develop, test, optimize, train and deploy AI agents across a wide range of use cases. We believe this collaboration and these resources should support QwikAgents’ mission to make powerful, persistent AI agents available not only to enterprises, but also to individual users , developers, and small businesses seeking affordable AI agent tools that are quick to deploy and designed with practical controls to support safer, more manageable use.” QwikAgents is developing a next-generation AI agent platform designed to make dedicated, persistent AI agents accessible to individuals, developers, small businesses and enterprises.